论文部分内容阅读
抗病毒药物可能成为治疗病毒复制活跃的慢性乙型肝炎的首选药物。但干扰素、阿糖腺苷或单磷酸阿糖腺苷单独用药仅能部分抑制乙型肝炎病毒相关性DNA多聚酶(HBV-DNAp),且副作用严重,因此不能大量使用或联合用药。作者比较了无环鸟苷(acyclovir,一种毒性较小的HBV-DNAp抑制剂)或干扰素单独用药与两者联合用药对慢性乙型肝炎患者病毒复制的影响。研究对象为12例慢性乙型肝炎患者,血清HBeAg和DNAp阳性至少6个月,其中11例已经肝活检证实肝细胞核内存在HBeAg。6例患者先用α干扰素(2.5MU/m~2,每日1次肌肉注射)4周,停药1个月再用无环
Antiviral drugs may be the drug of choice for the treatment of active chronic hepatitis B virus replication. However, interferon, vidadenosine or arabinosyl monophosphate alone can only partially inhibit the hepatitis B virus-associated DNA polymerase (HBV-DNAp), and serious side effects, it can not be used in large quantities or in combination. The authors compared the effects of acyclovir (a less toxic HBV-DNAp inhibitor) or interferon alone and in combination on the viral replication in patients with chronic hepatitis B. The subjects were 12 patients with chronic hepatitis B. The serum HBeAg and DNAp were positive for at least 6 months. 11 of them had been confirmed by liver biopsy as HBeAg in the nucleus of hepatocytes. 6 patients first with interferon alpha (2.5MU / m ~ 2, 1 intramuscular injection) for 4 weeks, withdrawal for 1 month and then acyclic